S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Hemogenyx Pharmaceuticals Share Forecast, Price & News

GBX 1.75
-0.08 (-4.11%)
(As of 01/14/2022 05:08 PM ET)
Today's Range
50-Day Range
52-Week Range
12.21 million shs
Average Volume
9.95 million shs
Market Capitalization
£17.15 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HEMO News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Hemogenyx Pharmaceuticals logo

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
Cash Flow
GBX 1.05 per share
Book Value
GBX 1 per share


Pretax Margin




Free Float
Market Cap
£17.15 million
Not Optionable

Company Calendar

Last Earnings


Overall MarketRank

0.77 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions

How has Hemogenyx Pharmaceuticals' stock price been impacted by Coronavirus?

Hemogenyx Pharmaceuticals' stock was trading at GBX 1.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HEMO stock has increased by 11.1% and is now trading at GBX 1.75.
View which stocks have been most impacted by COVID-19

How were Hemogenyx Pharmaceuticals' earnings last quarter?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter.
View Hemogenyx Pharmaceuticals' earnings history

Who are Hemogenyx Pharmaceuticals' key executives?

Hemogenyx Pharmaceuticals' management team includes the following people:
  • Dr. Vladislav Sandler Ph.D., Co-Founder, CEO & Director
  • Ms. Alexis M. Sandler J.D., Independent Co-Founder & Non-Exec. Director
  • Mr. Andrew Wright, Financial Controller & Company Sec.

What other stocks do shareholders of Hemogenyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Axon Enterprise (AAXN), Avaya (AVYA), Baidu (BIDU), Corbus Pharmaceuticals (CRBP), Curaleaf (CURLF), Heat Biologics (HTBX), Incyte (INCY), InMode (INMD), Intuitive Surgical (ISRG) and Remark (MARK).

What is Hemogenyx Pharmaceuticals' stock symbol?

Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hemogenyx Pharmaceuticals' stock price today?

One share of HEMO stock can currently be purchased for approximately GBX 1.75.

How much money does Hemogenyx Pharmaceuticals make?

Hemogenyx Pharmaceuticals has a market capitalization of £17.15 million.

How many employees does Hemogenyx Pharmaceuticals have?

Hemogenyx Pharmaceuticals employs 8 workers across the globe.

What is Hemogenyx Pharmaceuticals' official website?

The official website for Hemogenyx Pharmaceuticals is silverfalconplc.com.

Where are Hemogenyx Pharmaceuticals' headquarters?

Hemogenyx Pharmaceuticals is headquartered at 1st Fl Ofc 4, 50 Jermyn Street, LONDON, SW1Y 6LX, United Kingdom.

How can I contact Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals' mailing address is 1st Fl Ofc 4, 50 Jermyn Street, LONDON, SW1Y 6LX, United Kingdom. The company can be reached via phone at 44 79 0917 7311.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.